Summary of the Conference Call for Shangmei Co., Ltd. Company Overview - Shangmei Co., Ltd. is a research-driven cosmetics brand management company with over 20 years of operational history. The company's vision is to become an influential global cosmetics company, focusing on a "single focus, multi-brand, globalization" strategy. [3][4] Financial Performance - In 2025, the company achieved a revenue of 9.178 billion (up 35.1%) and a net profit of 1.154 billion (up 43.7%). The gross margin increased to 76.43%, and the return on equity (ROE) reached 40.2%. [2][7] - The company maintained a revenue and profit growth guidance of 25% for 2026, despite facing a public relations crisis in early 2026. [18] Brand Performance - **Han Shu**: Revenue in 2025 reached 7.36 billion (up 31.6%). The brand aims to achieve sales of 10-20 billion by 2030. [2][9] - **New Page**: Experienced explosive growth of 134.2%, reaching 880 million in revenue. [2][9] - **Anmi You**: Revenue in 2025 was 198 million (up 62.7%), with expectations to grow to 3-5 billion in the coming years. [9][21] - **Red Elephant**: Sales decreased due to demographic changes and brand adjustments. [9] Market Strategy - The company is shifting its channel structure towards online sales, which accounted for 93.9% of total sales in 2025. [2][8] - The company plans to expand into Southeast Asia with a localized strategy, having built a factory in Indonesia and set to start sales in 2026. [2][6] Product Development and Innovation - R&D investment reached 225 million (up 24%), focusing on proprietary ingredients like KT-939 for skin whitening. [2][7] - The company has established an AI-driven factory in Shanghai, capable of producing 2 million bottles daily. [4] Brand Matrix and Future Goals - The company has structured its brands into three tiers to mitigate risks: - **First Tier**: Han Shu (10-20 billion target) - **Second Tier**: Brands like New Page and Anmi You (2-8 billion target) - **Third Tier**: Brands like Red Elephant and Codemint (0-2 billion target) [5] Challenges and Recovery - Following a public relations crisis, Han Shu's business has stabilized and returned to positive growth by March 2026. [11][18] - The company is focusing on a "Five Good Strategy" for 2026, emphasizing good branding, ingredients, products, pricing, and experiences. [11] Trends and Future Product Launches - The company observes trends towards high efficacy and emotional value in products, with plans to launch new brands like Hello Kitty and collaborations with medical professionals. [15][16] - The company aims to expand its product lines to cover a broader age range, targeting 0-18 years and beyond. [13][22] Conclusion - Shangmei Co., Ltd. is positioned for significant growth with a robust multi-brand strategy, strong financial performance, and a commitment to innovation and market expansion. The company is adapting to market challenges while maintaining a focus on long-term goals and brand development. [17][24]

Summary of the Conference Call for 石四药集团 (Sihuan Pharmaceutical Group) Company Overview - **Company**: Sihuan Pharmaceutical Group - **Date of Call**: March 27, 2026 Key Financial Performance - **2025 Net Profit**: HKD 471 million, a decrease of 55.6% year-on-year, but the decline is less severe compared to the mid-year results [2][3] - **Sales Revenue**: Approximately HKD 4.165 billion, down 27.8% year-on-year; in RMB, it is about CNY 3.812 billion [3] - **Gross Margin**: Approximately 41.6%, down 8.8 percentage points year-on-year due to increased revenue share from centralized procurement and price declines in existing products [3] - **Dividend**: Maintained at HKD 0.08 per share, with a payout ratio close to 50% [3] - **Cash and Cash Equivalents**: Approximately HKD 1.69 billion at the end of 2025, an increase of HKD 433 million from the previous year [3] Business Segments and Growth Strategies Intravenous Solutions - **2026 Sales Target**: 1.85 billion bags (+20% growth) driven by the replacement of plastic bottles with upright bags and increased procurement [2][6] - **2025 Performance**: Sales volume of 1.536 billion bags, down 24.5%; sales revenue of HKD 2.485 billion, down 33.5% [6] Export Business - **2025 Export Growth**: Formulations export revenue increased by 35%, targeting HKD 300-350 million in 2026 [2][5] - **Packaging Materials**: Expected to double in growth, with significant market entry into Southeast Asia, South America, and the Middle East [5] Centralized Procurement - **Market Share**: Significant advantages in centralized procurement, with 12 products won in the 11th batch and plans to participate in 46 products in the 12th batch [2][4] Active Pharmaceutical Ingredients (APIs) - **Cost Advantage**: Self-produced calcium chloride and magnesium chloride at costs significantly lower than market prices (1/7 to 1/50) [2][11] - **2026 Outlook**: Expected recovery in business performance [2][11] Innovative Drugs - **Clinical Trials**: Plans to submit for Phase I clinical trials for pulmonary hypertension and epilepsy drugs by the end of 2026 [2][12] - **Partnerships**: Exclusive authorization for a sugar-free peritoneal dialysis solution from a Swiss company [2][17] Market Dynamics and Competitive Landscape - **Price Trends**: Continuous price decline in intravenous products, with a recent stabilization and expected price increases due to rising raw material costs [21][22] - **Market Share Concentration**: Centralized procurement is leading to increased market share for top-tier suppliers [22][23] Future Outlook - **2026 Goals**: Targeting 20% growth in intravenous solutions, with a focus on specialized products rather than standard saline solutions [15][22] - **Innovation Focus**: Plans to submit 2-3 Phase I clinical projects annually, leveraging AI for drug discovery [15][17] - **Export Revenue Target**: Expected formulation export revenue of HKD 300-350 million in 2026, with potential for further growth [17][18] Conclusion - **Management Confidence**: Despite recent challenges, the company is optimistic about returning to 2020 performance levels within two years, emphasizing shareholder value and strategic growth initiatives [24]

Summary of SenseTime Conference Call Company Overview - **Company**: SenseTime (0020.HK) - **Industry**: Artificial Intelligence (AI) Key Points Financial Performance - **2H25 Revenue**: Increased by 31% YoY to Rmb2.7 billion, exceeding estimates by 5% and consensus by 6% due to strong growth in the Gen-AI business [3][4] - **Gross Margin**: Improved to 43.2% in 2H25 from 42.0% in 2H24 and 38.5% in 1H25, attributed to a better product mix [3][4] - **Operating Expenses (Opex) Ratio**: Reduced to 97% in 2H25 from 162% in 2H24 and 127% in 1H25, indicating improved efficiency [3][4] - **Net Loss**: Narrowed to Rmb288 million in 2H25, better than estimates of Rmb1.1 billion and consensus of Rmb778 million [3][4] Future Projections - **Revenue Forecasts**: Revised 2026/27E net loss to Rmb774 million and Rmb73 million, respectively, reflecting faster-than-expected efficiency improvements [7] - **Earnings Growth**: Expected revenue growth of 33% in 2025 and 32% in 2026, with continued improvements in gross margins [11] Product Development - **New AI Model Launch**: Planned release of the new SenseNova AI model and updated NEO architecture in 2Q26, featuring advanced analytical and decision-making capabilities [2] - **Application Expansion**: AI applications will cover sectors such as education, office, marketing, and video generation, with a focus on consumer scenarios [2] Valuation and Investment Outlook - **Price Target**: Maintained at HK$3.55, with an implied 2027E EV/Sales valuation of 16x, aligning with the company's average EV/Sales since January 2023 [14][16] - **Investment Rating**: Maintained a "Buy" rating, with a potential upside of 90.9% from the current price of HK$1.86 [16] Risks - **Market Risks**: Potential risks include slower-than-expected customer ramp-up in generative AI, lower customer spending, and increased market competition [14] Additional Insights - **R&D Investment**: Continuous investment in AI technology is expected to drive future growth and efficiency [7] - **Operational Improvements**: Focus on enhancing employee productivity and operational efficiency is a key strategy moving forward [3][4] This summary encapsulates the essential insights from the conference call, highlighting SenseTime's financial performance, future projections, product development, valuation outlook, and associated risks.

Summary of Zhejiang Sanhua Conference Call Company Overview - **Company**: Zhejiang Sanhua - **Sector**: Auto Parts - **Description**: Sanhua primarily produces valves, pumps, and heat exchangers, with significant operations in refrigeration and auto thermal management systems. In 2024, refrigeration and auto components accounted for 60% and 40% of revenue, respectively [doc id='10'][doc id='11']. Key Financial Results - **4Q25 Performance**: - Revenue decreased by 5% YoY and 10% QoQ to RMB6,982 million, missing expectations by 21.9% [doc id='13']. - Gross Profit Margin (GPM) improved to 31.2%, up 4.3 percentage points YoY, while Operating Profit Margin (OPM) was 13.9%, down 1.4 percentage points QoQ [doc id='1']. - Net income fell 28% QoQ to RMB821 million, with a proposed FY25 cash dividend per share of RMB0.28, indicating a 29% payout ratio [doc id='1']. Segment Performance - **Refrigeration Business**: - Revenue grew 12% YoY, with organic growth at 7% after excluding data center and ESS cooling contributions [doc id='2']. - **Auto Parts Business**: - Revenue growth slowed to 9% from 15% in the previous year, with NEV-related sales growing only 5%, significantly lagging behind the overall China EV industry growth of 28% [doc id='2']. Margin Analysis - **Margins**: - GPM was higher than expected due to a time lag in cost adjustments. The divergence in net profit margins between refrigeration (9.7%) and auto parts (17.7%) widened in 2H25 [doc id='3']. - Concerns were raised about rising input costs, particularly aluminum, and a challenging downstream environment for auto parts, which may pressure margins despite hedging efforts [doc id='3']. Future Outlook and Estimates - **Earnings Growth**: - Management guided for a 15% earnings CAGR but noted limited visibility on top-line growth due to macroeconomic conditions [doc id='4']. - New strategic initiatives in data center and ESS cooling are expected to see revenue growth of 50-100% in 2026 [doc id='4']. - **Revised Estimates**: - Revenue and earnings estimates for 2026-27 were cut by 10% and 8% on average, respectively, due to slower auto parts growth [doc id='4'][doc id='14']. Valuation and Price Objective - **Price Objective**: - The price objective for Sanhua-H and Sanhua-A was lowered from HKD37/RMB53 to HKD30/RMB43, reflecting a reduced target P/E multiple for the auto/EV business from 20x to 15x [doc id='4'][doc id='12']. - **Valuation Methodology**: - A sum-of-the-parts (SOTP) valuation was applied, with a target P/E of 15x for both refrigeration and auto parts businesses, and 50x for the humanoid robot business [doc id='18'][doc id='20']. Risks - **Identified Risks**: - Potential lower growth in the refrigeration industry, deceleration in the auto/EV market, raw material price hikes, foreign exchange fluctuations, and geopolitical tensions [doc id='21'][doc id='24']. Additional Insights - **Market Position**: - Sanhua holds a strong market share in key components and is recognized globally in the thermal management industry, supported by robust R&D capabilities [doc id='19']. - **Future Growth Areas**: - Opportunities in humanoid robot actuators and liquid cooling solutions are seen as potential growth drivers, although current valuations appear stretched [doc id='11']. This summary encapsulates the key points from the conference call, highlighting the financial performance, segment analysis, future outlook, valuation adjustments, and associated risks for Zhejiang Sanhua.

Summary of Pop Mart International Group (9992.HK) Conference Call Company Overview - **Company**: Pop Mart International Group - **Ticker**: 9992.HK - **Sector**: General Consumer - **Market Cap**: USD 28,872.7 million as of March 25, 2026 [5][9] Key Financial Highlights - **FY25 Results**: - Revenue: CNY 37.12 billion, up 185% year-on-year, slightly below Bloomberg consensus of CNY 37.96 billion [1] - Adjusted Net Profit: CNY 13.08 billion, up 285% year-on-year, in line with consensus estimate of CNY 13.01 billion [1] - **FY26 Guidance**: - Management targets a conservative 20% year-on-year sales growth, a significant reduction from the previous CAGR of 100% from 2022-2025 [1] - Focus on operational improvements, including optimizing organizational structure and enhancing overseas execution [1] Target Price and Valuation - **Target Price**: Reduced to HKD 261.00 from HKD 372.00, reflecting a 55% upside from the closing price of HKD 168.30 [5][3] - **Valuation Method**: Based on a 20x target F12M P/E, adjusted for the anticipated slowdown in growth [3][18] Operational Insights - **IP Ecosystem**: - Pop Mart has developed a robust IP ecosystem that supports rapid growth across multiple IPs, with six IPs generating over CNY 2 billion in sales [2] - Offline boutiques serve as consumer gathering points, enhancing brand loyalty and market presence [2] - Potential for expansion into various product categories beyond plush and figure toys [2] Financial Projections - **Revenue Forecasts**: - FY26F: CNY 43.709 billion - FY27F: CNY 46.952 billion - FY28F: CNY 50.473 billion [4][17] - **Net Profit Forecasts**: - FY26F: CNY 15.142 billion - FY27F: CNY 16.417 billion - FY28F: CNY 18.101 billion [4][17] Risks and Challenges - **Key Risks**: - Geopolitical risks affecting overseas expansion - Weaker-than-expected domestic sales performance - Intensified competition in the pop toy market [12][26] Additional Insights - **ESG Commitment**: Pop Mart is focused on improving its ESG governance and management strategy, aiming to balance social and corporate value [13] - **Market Performance**: The stock has seen a decline of 27.7% over the past month and 15.9% over the past three months, but a 32.6% increase over the past year [9] This summary encapsulates the key points from the conference call regarding Pop Mart International Group, highlighting its financial performance, strategic focus, and market outlook.

Summary of Key Points from the Conference Call Records Company Overview - The company discussed is **Pop Mart**, focusing on its **LABUBU** IP and overall business strategy. Industry Insights - The **IP (Intellectual Property)** industry is highlighted, particularly in the context of collectible toys and related merchandise. Core Points and Arguments 1. **Revenue Growth and Projections** - For 2025, the company reported a total revenue of **371 billion** CNY, representing a **185%** year-on-year increase, with adjusted net profit at **131 billion** CNY, up **284%** [2] - The management set a revenue growth target of **no less than 20%** for 2026, emphasizing profit quality over mere revenue increase [1][2] 2. **LABUBU Performance** - LABUBU 3.0 series significantly contributed to Q3 revenue, with **6.33 billion** CNY recognized from pre-sales [1][2] - LABUBU's revenue for 2025 is projected at **142 billion** CNY, with a comparison to Pokémon's **840 billion** CNY indicating substantial growth potential [1][3] 3. **Market Penetration and Membership Growth** - The company reported **72.58 million** members in mainland China, a **57%** increase, with a repurchase rate of **55.7%** and a penetration rate of **16%** among the 20-44 age group [3] - The penetration rate in the U.S. is less than **1/10** of that in China, indicating significant overseas growth opportunities [3] 4. **New Business Ventures** - New business initiatives (theme parks, desserts, accessories, home appliances, and films) are positioned as IP operational strategies rather than immediate monetization tools [4] - The company aims to leverage its strong cash flow to invest in these ventures, enhancing its competitive edge [4] 5. **Valuation Insights** - Current market valuation is viewed as conservative, with potential upside if LABUBU is valued at **5x PE** and other IPs at **20x PE**, leading to an estimated market value of **1,850 billion** CNY [5][6] - Comparisons to Disney and Netflix suggest significant growth potential in valuation, with historical PE ratios indicating room for appreciation [6] 6. **Future Performance Expectations** - For 2026, the company anticipates achieving **53.5%** year-on-year growth in the first quarter, with expectations of high double-digit growth domestically and overseas [7] - The launch of LABUBU 4.0 has been delayed to the second half of 2026, which may alleviate growth pressure in the interim [7] Additional Important Insights - The management's analogy of 2026 as an "F1 pit stop" year reflects a strategic pause for recalibration after rapid growth, maintaining a focus on sustainable development [2] - The company’s strategy includes a diversified approach to new business ventures, allowing for experimentation without immediate profitability pressure [4] This summary encapsulates the essential insights from the conference call, providing a comprehensive overview of Pop Mart's current status and future outlook in the IP industry.

Summary of the Conference Call for Peijia Medical Company Overview - **Company**: Peijia Medical - **Industry**: Medical Devices, specifically focusing on structural heart disease and neurointervention Key Points Financial Performance - **2025 Revenue Growth**: Achieved a 15.8% increase in overall revenue, with core businesses (valve and neurointervention) showing significant cash flow improvements, rising from 0.2 billion to 0.7 billion RMB [2][3] - **Operating Cash Flow**: Core businesses generated positive cash flow of approximately 7 million RMB in 2025, a significant improvement from a negative cash flow of 20 million RMB [4][3] - **Cost Management**: Sales, management, and R&D expenses decreased in absolute terms, leading to a notable reduction in expense ratios, indicating effective operational leverage [3][4] Business Segments Performance - **Valve Business**: - 2025 saw approximately 3,900 valve implants, with a market share increase to 26.4% [2][5] - The TaurusElite valve for aortic regurgitation is expected to contribute 1,500 implants in 2026 [2] - The company aims for a 30% increase in implant volume in 2026, targeting 5,000 implants [3][11] - **Neurointervention Business**: - Revenue grew nearly 20% in 2025, with a market share of nearly 20% for thrombectomy stents, maintaining the leading position among domestic brands [2][8] - The DCY micro-guidewire received FDA approval, opening access to a global market worth 1.5 billion USD [2][9] Market Dynamics - **Impact of Healthcare Pricing Policies**: Recent adjustments in healthcare pricing have had a mild impact, with a significant increase in surgical volume expected in Q1 2026 [2][5] - **Product Portfolio**: The company has a competitive product pipeline, including first and second-generation products for aortic stenosis and the TaurusElite for aortic regurgitation, enhancing market competitiveness [5][6] International Expansion - **Outreach Strategy**: Focus on high-end markets in Europe and the US, with the GeminiOne mitral valve clip already registered in Europe [2][12] - **Funding for R&D**: The company plans to support R&D through external financing, particularly for cutting-edge technology without impacting core business cash flow [4][20] Future Outlook - **2026 Projections**: The company anticipates 2026 to be a year of accelerated growth, aiming for breakeven at the group level and significant revenue increases in both valve and neurointervention segments [11][29] - **Sales Strategy**: Emphasis on product differentiation and maintaining a comprehensive product line to address various market segments, ensuring resilience against price competition [17][18] Regulatory and Clinical Developments - **Clinical Trials**: Ongoing clinical trials for products like Monarch and GeminiOne, with expected advancements in regulatory approvals [20][21] - **Market Positioning**: The company is strategically positioned to leverage its innovative capabilities in the structural heart disease sector, aiming to enhance its reputation internationally [30] Competitive Landscape - **New Entrants**: The company acknowledges the challenges posed by new competitors but remains confident in its established market position and product competitiveness [27] Conclusion - **Long-term Strategy**: Peijia Medical is committed to balancing immediate financial performance with long-term growth potential, focusing on innovation and market expansion to enhance shareholder value [30]

Summary of Pop Mart (9992 HK) Conference Call Company Overview - **Company**: Pop Mart (9992 HK) - **Industry**: Specialty Retail Key Financial Highlights - **2025 Performance**: - Revenue increased by 185% year-on-year (y-o-y) to RMB 37,120 million - Net profit surged by 309% y-o-y to RMB 12,776 million - 4Q25 revenue was below expectations due to sequential contraction across most regions, except the Americas [1][12] - **IP Performance**: - 'The Monsters' (Labubu) IP led growth with a 366% y-o-y increase, contributing 38% to total revenue [1] - **Product Categories**: - Plush products were the main growth driver, with overseas markets contributing 50% to group revenue [1] 2026 Outlook - **Growth Normalization**: - Management anticipates a challenging 2026 with revenue growth expected to normalize to over 20% [2] - Revised earnings forecasts indicate net profit growth of 19% and revenue growth of 20% y-o-y, down from previous estimates of 21% and 24% [2] - **Margin Pressure**: - Rising raw material costs and changes in revenue mix may pressure gross profit margins, although cost controls are expected to partially offset this [2][22] Re-rating Potential - **Platform Scalability**: - Future growth will depend on the scalability of the IP platform and broadening growth across its IP portfolio [3] - **Valuation Metrics**: - Current 2026 P/E ratio is estimated at 12.8x, with potential for re-rating as earnings visibility improves [3] Target Price and Investment Recommendation - **Target Price Adjustment**: - Target price reduced by 6.9% to HKD 329.50 from HKD 354.00, reflecting a higher WACC of 11.4% due to short-term earnings uncertainty [4][24] - **Investment Rating**: - Maintain 'Buy' rating, implying a potential upside of approximately 96% based on the new target price [4][29] Financial Ratios and Estimates - **Earnings Estimates**: - EPS for 2025 is projected at RMB 9.81, with a decrease in estimates for 2026 and 2027 [8][14] - **Valuation Ratios**: - PE ratios for 2026 and 2027 are estimated at 12.8x and 10.2x, respectively [16] Risks and Considerations - **Company-Specific Risks**: - Potential supply chain issues, competition from new entrants, and risks related to IP licensing agreements [29] - **Market Risks**: - Economic disruptions affecting offline traffic and consumer behavior [29] Conclusion - Pop Mart has demonstrated significant growth in 2025, driven by its successful IP commercialization. However, the company faces challenges in 2026 as growth normalizes and margins are pressured. The investment recommendation remains positive, with a substantial upside potential based on the revised target price.

Summary of the Conference Call for Muyuan Foods (牧原股份) Company Overview - **Company**: Muyuan Foods (牧原股份) - **Industry**: Swine farming and meat processing Key Points Cost Management and Financial Targets - The target for swine farming costs in 2026 is set below **11.5 CNY/kg**, based on a cautious assumption of corn prices rising by **150 CNY/ton** [2][5] - The average cost in January-February 2026 rose to **12 CNY/kg** due to winter diseases, with expectations for a rapid decline in costs from March to May 2026 [2][9] - The company aims for a **dividend payout ratio** of no less than **40%** from 2024 to 2026, with an actual payout of **48%** in 2025 [2][8] Capital Expenditure Plans - The capital expenditure plan for 2026 is approximately **10 billion CNY**, with a focus on slaughtering operations [2][6] - The overseas expansion, starting with Vietnam, is expected to have a capital expenditure of around **1 billion CNY** in 2026, with significant investments anticipated in 2027 and beyond [2][5] Production and Operational Efficiency - The company is implementing measures to enhance production efficiency, including disease prevention, employee incentives, breeding improvements, and AI technology applications [3][4] - The breeding program focuses on overall profitability rather than single metrics, aiming to improve reproductive performance, growth rates, slaughter performance, and meat quality [4] Market Conditions and Challenges - The current market is challenging, with low pig prices affecting the industry. The company is focusing on providing value to farmers through quality products and services [7][10] - The company has not set aggressive debt reduction targets, prioritizing cash flow stability during this market downturn [6][10] Slaughtering Business Growth - The slaughtering business is expected to achieve double-digit growth in 2026, leveraging existing capacity and potential new investments [2][13] - The company does not plan to use pork inventory for speculative purposes, focusing instead on fulfilling customer orders [2][19] Employee Management and Cost Control - The reduction in employee numbers to **127,500** in 2025 is attributed to improved management efficiency and not a strategic shift [14] - The company aims to enhance the capabilities of underperforming farms through better management and training [11] Future Outlook - The company anticipates that the current low cycle in the swine industry may persist, but it is prepared to navigate through it with a focus on operational stability and cost management [12][16] - The company is cautious about future dividend increases, maintaining the current payout ratio until operational results improve [8][10] Accounting and Financial Adjustments - Recent changes in accounting treatment for government subsidies will not affect the overall financial position but may impact gross margins [17] Conclusion - Muyuan Foods is strategically positioned to manage costs and expand its operations despite current market challenges, with a clear focus on maintaining financial stability and operational efficiency while navigating the complexities of the swine industry.

Summary of Mao Geping Cosmetics Co. (1318.HK) Earnings Call Company Overview - **Company**: Mao Geping Cosmetics Co. (1318.HK) - **Market Cap**: HK$34.1 billion / $4.4 billion - **Industry**: Cosmetics Key Financial Highlights - **2H25 Performance**: - Sales growth of 29% year-over-year (yoy) to RMB2,462 million, 1% above Goldman Sachs estimates (GSe) [1] - Net income (NI) increased by 38% yoy to RMB534 million, largely in line with consensus [1][25] - Full year 2025 revenue reached RMB5,050.5 million, up 30% yoy, consistent with GSe [1][18] - Adjusted NI for 2025 grew 31% yoy to RMB1,209 million, slightly below GSe [1] - **Margins**: - Gross profit margin (GPM) expanded by 0.4 percentage points (ppt) yoy to 84.3%, exceeding GSe [22] - Operating profit margin (OPM) increased by 1.1ppt yoy to 27.3%, also above GSe [24] - Net margin expanded by 1.4ppt yoy to 21.7%, slightly below GSe [25] - **Dividend**: - Declared a final dividend of RMB1.00 per share, implying a 41% payout ratio, above GSe of 30% [26] Sales Breakdown - **By Category**: - Color cosmetics sales grew by 29% yoy in 2H25 to RMB1,574 million, representing 64% of total sales [19] - Skincare sales increased by 28% yoy to RMB786 million, accounting for 32% of total sales [19] - **By Channel**: - Offline sales rose by 22% yoy to RMB1,202 million, with DTC sales growing by 24% yoy [20] - Online sales surged by 39% yoy to RMB1,180 million, with online DTC sales increasing by 33% yoy [22] Future Outlook - **2026 Estimates**: - Expected sales of RMB6.6 billion and NI of RMB1.5 billion, representing growth of 30% and 28% yoy respectively [2][29] - Target price (TP) revised to HK$106, implying a 52.2% upside from current price [1][30] - **Growth Drivers**: - Anticipated strong growth in online and offline channels, with 40% and 21% growth expected respectively in 2026 [3] - Continued focus on margin sustainability and ROI across channels [17] Valuation Metrics - **P/E Ratios**: - 2026E P/E at 35.5x, decreasing to 19.5x by 2026E and further to 16.5x by 2027E [11] - Target P/E exit multiple remains at 28x, reflecting a 30% premium to industry base multiple [30] Additional Insights - **Operational Efficiency**: - Selling and distribution expenses increased by 31% yoy, but admin expenses decreased by 1% yoy, indicating improved operational efficiency [23] - Effective tax rate decreased by 0.6ppt yoy to 24.5% [24] - **Market Position**: - Company is positioned to deliver the fastest growth among covered cosmetics companies, supported by a robust product pipeline and strategic initiatives [3][17] This summary encapsulates the key points from the earnings call, highlighting the company's performance, future outlook, and valuation metrics.